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S208 Poster Session Ipatients (93%) completed collection within the predicted number of
apheresis sessions (78% for G and 100% for G + P, P5 0.03). Nine-
teen (68%) of the patients included in the validation cohort have re-
ceived a first autologous transplant. Median cell dose was 3.81 106
(range 3.04-4.42 x106) CD34+/kg for the 8 patients in the G ap-
proach and 4.99  106 (range 3.00-7.49 x106) CD34+/kg for the
11 patients in the G + P approach. There was no difference between
approaches in time for absolute neutrophil count. 500/mm2 (me-
dian 12 days vs. 13 days for G and G + P respectively, P5 0.07) or
platelet count. 20,000/mm2 without platelet transfusion (median
11.5 days vs. 13 days for G and G + P respectively, P5 0.09)
Conclusion: The MUSC mobilization algorithm is a data-gener-
ated and accurate tool to decide on the utilization of plerixafor for
mobilization, starting on the 4th day of G-CSF. This approach is
likely to save on mobilization costs compared to the ‘‘on label’’ use
of plerixafor in all MM and NHL mobilizations.
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READMISSION RATES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Mohan, S., Overman, R., Dean, R., Smith, S., Kalaycio,M., Pohlman, B.,
Sweetenham, J., Sobecks, R., Andresen, S., Copelan, E., Bolwell, B. Cleve-
land Clinic Taussig Cancer Institute, OH
With increasing scrutiny of healthcare expenditures, policy pro-
posals have highlighted the reduction in hospital readmission rates
as a method by which to improve the cost and the quality of medical
care. To date, readmission rates following bone marrow transplanta-
tion procedures have been sparsely described. A retrospective review
of consecutive patients who underwent autologous hematopoietic
stem cell transplantation (AHSCT) at a single institution over
a five-year period was performed to determine the number and
causes of readmission within one year post-transplantation. Each re-
admission was classified according to the primary presenting symp-
tom or an identified etiology following inpatient clinical evaluation.
485 patients received high-dose chemotherapy followed by an
AHSCT from 1/2004 to 12/2008 for varied disease indications in-
cluding non-Hodgkin lymphoma (n5 252, 52%), multiplemyeloma
and/or amyloidosis (124, 26%), Hodgkin lymphoma (83, 17%), and
other malignant diseases (26, 5%). Of these, 142 (29%) required at
least one inpatient readmission within one year, accounting for
216 discrete events. 45 patients (9%) were readmitted more than
once. 60 of all readmissions (28%) occurred within the first 30
days of transplantation, and 131 (61%) within the first 100 days.
45% of all readmissions were due to infection or unexplained fever,
17% to gastrointestinal causes, 13% to relapsed disease or new sec-
ondary malignancy, 8% to cardiopulmonary symptoms, and 6% to
neurological symptoms, with the remainder of admissions related
to thromboembolic disease, refractory pain symptoms, hepatic dys-
function, or other causes. Among those patients admitted within
30 days, 63% presented with infection or fever and 23%with gastro-
intestinal symptoms. The majority of those readmitted with gastro-
intestinal toxicity (9/14) were patients with non-Hodgkin
lymphoma. Further study of this high-risk patient group and of the
reasons for readmissionmay identify outpatient supportive caremea-
sures that could be enacted to decrease both AHSCT-related mor-
bidity and associated healthcare costs.135
PLERIXAFOR GIVEN ‘‘JUST IN TIME’’ FOR PERIPHERAL BLOOD STEM
CELL MOBILIZATION OF PATIENTS WITH SUBOPTIMAL RESPONSE TO
G-CSF
Horwitz, M., Khan, T., Long, G., Gasparetto, C., Sullivan, K., Chute, J.,
Rizzieri, D., Drago, S., Chao, N. Duke University Health System, Dur-
ham, NC
Plerixafor reversibly inhibits binding of stromal cell-derived factor
1 alpha to the chemokine receptor CXCR4 resulting in mobilization
of bone marrow hematopoietic progenitor cells. Phase III studies
demonstrate that plerixafor given on day 4 of G-CSF treatment sig-
nificantly improves the chances of successful peripheral blood stemcell collection compared to G-CSF alone in patients with multiple
myeloma (MM) and non-Hodgkin lymphoma (NHL). In the context
of an IRB approved phase II clinical trial, we studied whether plerix-
afor could be used to rescue patients who demonstrate a suboptimal
mobilization response to five doses of G-CSF(10mg/kg). Patients
were eligible for protocol therapy if, on day 5 of G-CSF, there was
less than 7 circulating CD34+ cells/ml. In addition, patients with 7
to 20 circulating CD34+ cells/ml were eligible for protocol therapy
if \1.3  106 CD34+ cells/kg were collected on the first day of
apheresis. These patients were felt to be at high-risk for inadequate
stem cell collection. Subjects were given plerixafor (0.24 mg/kg) at
10:00PMof day 5 of G-CSF therapy. This process of an evening dos-
ing with plerixafor followed the next morning by G-CSF and apher-
esis was repeated for up to a total of 3 days of apheresis or until$5
106 cells/kg were collected. The primary endpoint of the study is the
percentage of patients who collected at least 2 106 CD34+ cells/kg.
Nine subjects (median age 59) have been accrued to the trial (MM 3,
NHL 5, Hodgkin Lymphoma 1), with the results demonstrated in
the table. Five of nine subjects had less than 7 circulating CD34+
cells/kg on Day 5 of G-CSF mobilization. The circulating CD34+
cell level increased a mean of 2.8 fold after the first dose of plerixafor
and a mean of 1.8 fold after the second dose of plerixafor. All nine
subjects achieved the primary endpoint of the study (collection of
.2 106 CD34+ cells/kg). Plerixafor was well tolerated with no ad-
verse events.grade 1. In conclusion, plerixafor can be given ‘‘just in
time’’ to rescue patients with a poormobilization response toG-CSF
alone. Further studies are needed to assess themost cost effective way
of using this potent stem cell mobilizing agent.
Mobilization Response to Plerixafor given ‘‘Just in Time’’
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RITUXIMAB AND SARGRAMOSTIM IMMUNOTHERAPY FOLLOWING AU-
TOLOGOUS STEM CELL TRANSPLANT FOR AGGRESSIVE NON-HODGKIN’S
LYMPHOMA
Scigliano, E., Grosskreutz, C.L., Osman, K., Malone, A., Nieto, J.,
Isola, L.M. Mount Sinai Medical Center, New York, NY
Introduction: High dose chemotherapy with autologous stem cell
transplant (ASCT) improves survival in patients with aggressive
non-Hodgkin’s lymphoma (NHL), but relapse occurs in 40-50%
of patients. Rituximab exerts its anti-tumor effect through comple-
ment and antibody-dependent cell cytotoxicity (ADCC). Sargramos-
tim is involved in the activation and differentiation of macrophages
and dendritic cells and increases monocyte-mediated ADCC. The
addition of sargramostim to rituximabmay potentiate the anti-tumor
effect of rituximab by enhancing recruitment and activation of effec-
tor cells that mediate ADCC.We evaluated the safety and efficacy of
rituximab and sargramostim given as ‘‘adjuvant immunotherapy’’ to
patients following ASCT for aggressive NHL.
Patients andMethods: 8 patients (5 male, 3 female; median age 53,
range 34-69) with CD20+ diffuse large B cell (6) or mantle cell (2)
NHL relapsed, primary refractory or in first complete remission (in-
termediate-high or high risk IPI) underwent stem cell mobilization
using rituximab and cyclophosphamide followed by high dose
